Hematology Reports · Published 2026-07-27 · DOI 10.3390/hematolrep18040052
Philip Yeung, Aaron Trando, Ah-Reum Jeong, Dimitrios Tzachanis
<b>Background/Objectives</b>: CAR T-cell therapy is a highly efficacious therapy option for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), but its widespread use is currently limited by safety concerns and high healthcare costs. <b>Methods</b>: We evaluated 66 patients with R/R LBCL treated with tisagenlecleucel or axicabtagene ciloleucel between 2016 and 2022 at a single institution to identify factors associated with increased healthcare utilization. <b>Results</b>: The median age of our cohort was 59.5 years, with 22.7% over the age of 70. The median length of stay (LOS) during the initial hospitalization was 12 days (range, 7–62 days). Longer initial hospital LOS was linked to higher age-adjusted HCT-CI score (IRR 1.08; 95% CI, 1.01 to 1.15; <i>p</i> = 0.0203), thrombocytopenia grade 3–4 (IRR 1.32; 95% CI, 1.07 to 1.63; <i>p</i> = 0.0091), and first ICU admission (IRR 1.81; 95% CI, 1.37 to 2.38; <i>p</i> < 0.00001). Thirty- and 90-day readmission rates post-discharge after receiving CAR T-cell therapy were 21.2% and 28.8%, respectively. Multiple readmissions within 90 days after initial hospital discharge were observed in 15% of patients. Longer 30-day readmission LOS was linked to initial hospital LOS (IRR 1.23; 95% CI, 1.11 to 1.35; <i>p</i> < 0.0001) but outpatient follow-up was associated with shorter 30-day readmission LOS (IRR 0.43; 95% CI, 0.26–0.69; <i>p</i> = 0.0005). Factors associated with longer 90-day readmission LOS included a greater number of ER visits within 60 days of CAR T-cell therapy (IRR 3.10; 95% CI, 2.15–4.46), prior 30-day readmission LOS (IRR 1.35; 95% CI, 1.14–1.60), and SUVmax at Day 30 (IRR 1.06; 95% CI, 1.03–1.09) (all <i>p</i>-values < 0.0001). <b>Conclusions</b>: Our findings identify key clinical and utilization variables associated with initial and repeat hospitalizations post-CAR T-cell therapy, emphasizing the need for targeted interventions to reduce readmissions and optimize post-discharge care.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Yeung, P., Trando, A., Jeong, A., et al. (2026). Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL. Hematology Reports. https://doi.org/10.3390/hematolrep18040052